Advertisement

Investigational New Drugs

, Volume 11, Issue 4, pp 329–331 | Cite as

A phase II trial of piroxantrone in adenocarcinoma of the pancreas

A Southwest Oncology Group Study
  • Terry R. Jenkins
  • Catherine Tangen
  • John S. Macdonald
  • Geoffrey Weiss
  • Robert Chapman
  • Alexander Hantel
Phase II Clinical Trials Brief Report

Summary

Thirty-five evaluable patients with advanced adenocarcinoma of the pancreas were treated with piroxantrone at a dose of 150 mg/m2 intravenously every 21 days. No objective responses were observed (95% confidence interval 0% –10%). Toxicities of grade ≥ 3 were primarily hematologic and were seen in 28 patients. Piroxantrone is inactive in pancreatic cancer and no further investigation of this agent in this tumor is recommended.

Key words

piroxantrone adenocarcinoma of the pancreas 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Boring CC, Squires TS, Tong T: Cancer Statistics, 1991. Ca 41:19–36, 1991PubMedGoogle Scholar
  2. 2.
    Brennan MF, Kinsella TJ, Friedman M: Cancer of the Pancreas.In DeVita VT, Hellman S, Rosenberg SA: Cancer Principles and Practice of Oncology, pp. 800–835. Philadelphia, JB Lippincott, third edition, 1989Google Scholar
  3. 3.
    Showalter HD, Johnson JL, Werbel LM, Leopold WR, Jackson RC, Elslager EF: 5-[(aminoalkyl)amino] substituted anthra[1,9-cd]pyrazol-6(2h)-ones as novel anticancer agents. Synthesis and biological evaluations. J Med Chem 27:253–255, 1984PubMedGoogle Scholar
  4. 4.
    Leopold WR, Nelson JM, Plowman J, Jackson RC: Anthrapyrazoles, a new class of intercalating agents against murine tumors. Cancer Res 45:5532–5539, 1985PubMedGoogle Scholar
  5. 5.
    Burchenal J, Pancoast T, Elslayer E: Anthrapyrazole and amsacrine analogues in mouse and human leukemiain vitro andin vivo. Proc Am Assoc Cancer Res 26:339, 1985Google Scholar
  6. 6.
    Hantel A, Donehower RC, Rowinsky EK, Vance E, Clarke BV, McGuire WP, Ettinger DS, Noe DA, Grochow LB: Phase I study and pharmacodynamics of piroxantrone (NSC 349174), a new anthrapyrazole. Cancer Res 50:3284–3288, 1990PubMedGoogle Scholar
  7. 7.
    Miller A, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47:207–214, 1981PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1993

Authors and Affiliations

  • Terry R. Jenkins
    • 1
  • Catherine Tangen
    • 2
  • John S. Macdonald
    • 3
  • Geoffrey Weiss
    • 4
  • Robert Chapman
    • 5
  • Alexander Hantel
    • 6
  1. 1.Brooke Army Medical CenterSan Antonio
  2. 2.Southwest Oncology Group Statistical CenterSeattle
  3. 3.Temple UniversityPhiladelphia
  4. 4.University of Texas Health Science CenterSan Antonio
  5. 5.Henry Ford HospitalDetroit
  6. 6.Loyola University Stritch School of MedicineMaywoodUSA

Personalised recommendations